$OCGN News
Last published 1d ago
- 1d agoOCGNOcugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEANGlobeNewswireCelairis receives exclusive rights to commercialize OCU400, Ocugen's investigational modifier gene therapy for retinitis pigmentosa (RP), in Australia, New...
- 1w agoOCGNOcugen, Inc. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoOCGNOcugen, Inc. Q3 2026 Financial Results and Business Highlights - OCUGEN INCEarnings Call TranscriptsGood morning and welcome to Ocugen's third quarter 2026 financial results and business update. All participants are currently in listen-only mode. Following the speaker's commentary, there will be a question and answer s
- 1w agoOCGNOcugen Provides Business Update with Third Quarter 2026 Financial ResultsGlobeNewswireConference Call and Webcast Today at 8:30 a.m. ET Received Provisional Approval and Priority Designation for OCU400 in The Bahamas Executed agreement with local partner Global Alliance for Regenerative Medicine (GARM)
- 1w agoOCGNOcugen to Participate in Upcoming November Investor and Industry ConferencesGlobeNewswireMALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company
- 2w agoOCGNOcugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4GlobeNewswireMALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, will host a
- 4w agoOCGNOcugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North AfricaGlobeNewswireEstablishes strategic commercial reach across the Middle East and North Africa, advancing Ocugen’s goal of enabling global patient access to potentially transformational gene therapiesExpands access to a potential
- 1mo agoOCGNDid Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireShareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket
- 2mo agoOCGNOcugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationGlobeNewswireThe single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine Advanced Therapy
- 2mo agoOCGNOcugen to Participate in Upcoming September Investor and Industry ConferencesGlobeNewswireMALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will
- 3mo agoOCGNOCUGEN CG 46TH ANNUAL GROWTH CONFERENCE - OCUGEN INCEarnings Call TranscriptsExcellent. All right. Thank you everyone for joining us this afternoon. My name is Whitney Egyem. I'm one of the biotech analysts here at Canaccord. And it's my pleasure to be joined by Akhijan this afternoon and the cha
- 3mo agoOCGNOCUGEN CG 46TH ANNUAL GROWTH CONFERENCE - OCUGEN INCEarnings Call TranscriptsExcellent. All right. Thank you everyone for joining us this afternoon. My name is Whitney Egyem. I'm one of the biotech analysts here at Canaccord. And it's my pleasure to be joined by Akhijan this afternoon and the cha
- 3mo agoOCGNOcugen, Inc. Q2 2026 Financial Results and Business Highlights - OCUGEN INCEarnings Call TranscriptsGood morning and welcome to Ocugen's second quarter 2036 Financial Results and Business Update. All participants are in this and all the mode. Following the speaker's commentary, there will be a question and answer sessi
- 3mo agoOCGNOcugen Provides Business Update with Second Quarter 2026 Financial ResultsGlobeNewswireConference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related macular
- 3mo agoOCGNOcugen to Participate in Upcoming August Investor ConferencesGlobeNewswireMALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will
- 3mo agoOCGNOcugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular DegenerationGlobeNewswireRMAT designation is intended to help expedite development of new regenerative medicines that have potential to treat serious medical conditions with significant unmet needThe designation could accelerate OCU410’s
- 3mo agoOCGNOcugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial ResultsGlobeNewswireMALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a
- 4mo agoOCGNOcugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North AfricaGlobeNewswireCumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., July 13, 2026 (GLOBE
- 4mo agoOCGNOcugen to Participate in Upcoming July Industry ConferencesGlobeNewswireMALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will
- 5mo agoOCGNOcugen to Participate in Upcoming June Investor and Industry ConferencesGlobeNewswireMALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will
- 5mo agoOCGNSTIFEL 2026 VIRTUAL OPHTHALMOLOGY FORUM - OCUGEN INCEarnings Call TranscriptsHi, good morning, everyone, and welcome to the Ocugen session. Ocogen is in the gene therapy world, not for systemic diseases, but for retinal diseases, which is very localized and gives the company a very different risk
- 6mo agoOCGNOcugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior NotesGlobeNewswireMALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of $130.0
- 6mo agoOCGNOcugen to Participate in Upcoming May Scientific and Investor ConferencesGlobeNewswireMALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will
- 6mo agoOCGNOcugen Provides Business Update with First Quarter 2026 Financial ResultsGlobeNewswireConference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p<0.05) 31% reduction in
- 6mo agoOCGNOCUGEN, INC. Q1 2026 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS - OCUGEN INCEarnings Call TranscriptsGood morning and welcome to Oxygen First Quarter 2026, Financial Result and Business Update. All participants' lines are currently in listen-only mode. Following the speaker commentary, there will be a question-and-answe
- 6mo agoOCGNOcugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior NotesGlobeNewswireMALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen") (NASDAQ:OCGN) today announced the pricing of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the "notes") in a
- 6mo agoOCGNOcugen Announces Private Offering of $115 Million of Convertible Senior NotesGlobeNewswireMALVERN, Pa., May 04, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced its intention to offer,
- 6mo agoOCGNOcugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial ResultsGlobeNewswireMALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a
- 6mo agoOCGNOcugen to Present at April 2026 Investor and Industry ConferencesGlobeNewswireMALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar
- 7mo agoLCTXOCGNVRTXLGVNBiotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated CellsPR NewswireFor most of modern biology, aging has been treated as a backdrop — the inevitable canvas on which individual diseases are painted. That is beginning...
- 7mo agoOCGNOcugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt DiseaseGlobeNewswireGARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time modifier gene therapy
- 7mo agoOCGNPhase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - OCUGEN INCEarnings Call TranscriptsGood morning, and welcome to OxyGEN's webcast to discuss the top-line 12-month results from Phase II Armada Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-Related Macular Degeneration.
- 7mo agoOCGNOcugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationGlobeNewswireOptimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05)Potential 2X treatment benefit compared to 15% and 22% reductions reported
- 7mo agoOCGNOcugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic AtrophyGlobeNewswireMALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a
- 8mo agoOCGNOcugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireEnrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected in the first quarter
- 8mo agoGERNNTLANAGEOCGNInvestors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B MilestonePR NewswireMarket News Updates News Commentary - The global anti-aging therapy market is gaining serious momentum as people live longer and actively look for...
- 8mo agoOCGNOcugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis PigmentosaGlobeNewswireEnrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patientsTopline Phase 3
- 8mo agoOCGNOcugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireMALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a
- 9mo agoOCGNOcugen Appoints Rita Johnson-Greene to Chief Financial OfficerGlobeNewswireMALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita
- 9mo agoOCGNOcugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common StockGlobeNewswireMALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced
- 9mo agoOCGNOcugen, Inc. Announces Pricing of $22.5 Million Offering of Common StockGlobeNewswireMALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pricing of its underwritten offering of
- 10mo agoOCGNOcugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationGlobeNewswirePhase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical trials to date
- 10mo agoOCGNOcugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial DataGlobeNewswireMALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a
- 10mo agoOCGNOcugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene TherapyGlobeNewswireStudy supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease patients MALVERN, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen
- 10mo agoOCGNOcugen CEO to Present at J.P. Morgan 2026 Healthcare ConferenceGlobeNewswireMALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri,
- 11mo agoOCGNOcugen CEO to Present at Oppenheimer Movers in Rare Disease SummitGlobeNewswireMALVERN, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri,
- 11mo agoOCGNOcugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity ConferenceGlobeNewswireMALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri,
- 1y agoOCGNOcugen Provides Business Update with Third Quarter 2025 Financial ResultsGlobeNewswirePhase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA) provided acceptability
- 1y agoOCGNOcugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial ResultsGlobeNewswireMALVERN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a
- 1y agoOCGNOcugen to Present at Industry and Investor Conferences in October 2025GlobeNewswireMALVERN, Pa., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that executive